title: Recent advances in T-cell engineering for use in immunotherapy.
abstract: Adoptive T-cell therapies have shown exceptional promise in the treatment of cancer, especially B-cell malignancies. Two distinct strategies have been used to redirect the activity ofex vivoengineered T cells. In one case, the well-known ability of the T-cell receptor (TCR) to recognize a specific peptide bound to a major histocompatibility complex molecule has been exploited by introducing a TCR against a cancer-associated peptide/human leukocyte antigen complex. In the other strategy, synthetic constructs called chimeric antigen receptors (CARs) that contain antibody variable domains (single-chain fragments variable) and signaling domains have been introduced into T cells. Whereas many reviews have described these two approaches, this review focuses on a few recent advances of significant interest. The early success of CARs has been followed by questions about optimal configurations of these synthetic constructs, especially for efficacy against solid tumors. Among the many features that are important, the dimensions and stoichiometries of CAR/antigen complexes at the synapse have recently begun to be appreciated. In TCR-mediated approaches, recent evidence that mutated peptides (neoantigens) serve as targets for endogenous T-cell responses suggests that these neoantigens may also provide new opportunities for adoptive T-cell therapies with TCRs.
authors.affiliation: Department of Biochemistry, University of Illinois, Urbana, IL, USA.
authors.forename: Preeti
authors.initials: P
authors.lastname: Sharma
authors.affiliation: Department of Biochemistry, University of Illinois, Urbana, IL, USA.
authors.forename: David M
authors.initials: DM
authors.lastname: Kranz
keywords: T cell; chimeric antigen receptor; immunotherapy; neoantigens; receptor